2102 Study (Hepatic)

The purpose of Study 2102 is to evaluate the safety and tolerability of an investigational treatment for various types of cancer in people with hepatic impairment compared with individuals without liver impairment.

This treatment has already been tested both in healthy volunteers and people with cancer. The goal of this study is to better understand how the medication is metabolized by people with moderate to severe liver impairment/cirrhosis. This is a vital step in the development of new medication, so that people with moderate to severe liver impairment can be given the correct dose when/if the medication is approved.

Reimbursement for study participation will be provided for time and travel of up to $1,700.